• Mashup Score: 1

    Severe asthma presents a major challenge to health care and negatively affects the quality of life of patients. Understanding the factors predicting the development of severe asthma is limited.

    Tweet Tweets with this article
    • Although patients with severe asthma constitute a fraction of the total asthma patients, severe asthma treatment contributes a high proportion to the total economic burden. Understanding patient factors underlying severe asthma is thus a key priority. https://t.co/5XyJPHB5cJ

  • Mashup Score: 0

    Sublingual immunotherapy (SLIT) is a safe, effective therapy for the treatment of food allergy. Studies demonstrating SLIT efficacy have primarily used pharmaceutical glycerinated food extracts for the administration of food allergens, which may limit accessibility due to extract cost and availability.

    Tweet Tweets with this article
    • In addition to pharmaceutical-grade options, the creation of standardized real-food sublingual immunotherapy protocols for use in real-world settings may allow more allergists to consider incorporation of SLIT in their own clinical practice. https://t.co/DqMKDDz6Pq

  • Mashup Score: 0

    Oral Immunotherapy (OIT) has exhibited great potential in the treatment of food allergy. However, there is no global consensus on best practices of OIT. Parents of allergic children often struggle with concerns regarding OIT methodology, safety, and lack of accessible educational resources. ChatGPT is a generative artificial intelligence chatbot from OpenAI recognized for its ability to formulate human-like conversations. Although applications of artificial intelligence in medical settings continue to be explored, the effectiveness of ChatGPT as an educational resource remains unknown for OIT.

    Tweet Tweets with this article
    • Oral Immunotherapy has exhibited great potential in food allergy treatment. However, there is no consensus on best practices of OIT education. This study assesses ChatGPT accuracy as a self-guided educational resource for parents of children getting OIT. https://t.co/8APxu9XnvG

  • Mashup Score: 4

    Knowledge and understanding of mast cell biology and mast cell disorders has increased in the past several years, with new classifications of diseases for both clonal and non-clonal forms. Along with these classifications has come differing treatment paradigms, including novel therapies now approved for various forms of clonal mast cell disorders. Unfortunately, there is some lack of guidance on how best to utilize these therapies. This yardstick aims to provide the clinician with a review of available therapies to treat mast cell activation syndrome and indolent systemic mastocytosis and an evidence-based expert opinion approach regarding how best to utilize these therapies.

    Tweet Tweets with this article
    • This yardstick provides the clinician with a review of available therapies to treat mast cell activation syndrome and indolent systemic mastocytosis and an evidence-based expert opinion approach regarding how best to utilize these therapies. https://t.co/05YSd92IJ3

  • Mashup Score: 2

    The past decade has seen a proliferation in biologic therapies for moderate to severe asthma, with 5 therapies gaining US Food and Drug Administration (FDA) approval in 6 years. Though this treatment expansion adds new opportunities for patients with previously untargeted phenotypes or previous biologic failure, it has also increased the complexity of selecting the most appropriate biologic for each individual. The choice of a biologic may be on the basis of administration frequency, safety, and comorbidity treatment but is often heavily influenced by phenotype- and biomarker-directed clinical efficacy.

    Tweet Tweets with this article
    • The choice of a biologic may be based on administration frequency, safety, & comorbidity treatment but is influenced by phenotype- and biomarker-directed clinical efficacy. Learn how weighing real-world studies can reflect outcomes in clinical practice. https://t.co/NmFnNcuKvF

  • Mashup Score: 4

    Chronic rhinosinusitis is a common inflammatory condition that often leads to significant sleep disturbances, negatively affecting quality of life. Although intranasal steroids are a standard treatment, their effect on sleep disturbances in chronic rhinosinusitis has not been extensively studied.

    Tweet Tweets with this article
    • Chronic rhinosinusitis is a common inflammatory condition that often leads to significant sleep disturbances, negatively affecting quality of life. This study aims to find whether a nasal steroid delivered through exhalation could improve sleep quality. https://t.co/e7e7N4IxyT

  • Mashup Score: 0

    Mast cell activation syndrome (MCAS) is a heterogeneous, uncommon entity presenting with acute, recurrent episodes of severe systemic symptoms, which may have clonal or nonclonal etiologies. These symptoms are associated with the excessive release of mast cell (MC) mediators and often present as anaphylaxis.1-3 Recently, MCAS has gained increased recognition from both the general public and medical providers; however, there remains considerable confusion in its diagnosis due to many gaps in knowledge in this field.

    Tweet Tweets with this article
    • Recently, mast cell activation syndrome has gained increased recognition from both the public and medical providers; however, there remains considerable confusion in its diagnosis due to many gaps in knowledge. Learn how this master clinician proceeds. https://t.co/qIqudyy70f

  • Mashup Score: 1

    Obesity is a risk factor for poor asthma control. Previous research suggests that patients with asthma and obesity have reduced responsiveness to corticosteroids. Recent studies indicate that body fat percentage may be more strongly associated with obesity-related diseases compared with body mass index. However, the relationship between body fat percentage and asthma, particularly regarding steroid sensitivity, remains unclear.

    Tweet Tweets with this article
    • A study investigates the association between body fat percentage and steroid sensitivity in patients with asthma and clarifies the potential mechanisms underlying this association. Is there a potential therapeutic approach for this population? Learn more https://t.co/P6lF0rrYyi

  • Mashup Score: 1

    Atopic dermatitis (AD) is a common inflammatory skin condition with US prevalence from 10% to 15% for children and 7% to 10% for adults.1 In 2023, a joint task force for practical parameters funded by the American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma and Immunology published updated evidence-based AD guidelines.2 In the following figure, we outline our treatment approach, refined from years of practical experience working with complex pediatric and adult patients with AD, which is closely aligned with these publications.

    Tweet Tweets with this article
    • Atopic dermatitis is a common inflammatory skin condition with US prevalence from 10% to 15% for children and 7% to 10% for adults. See Annals' latest Master Clinician Series article on "How we treat severe atopic dermatitis." https://t.co/yyaL3YBkw3